AMANDA FORD: Open Payments
NPI 1417532292 · HOT SPRINGS, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,400 in 165 payments from 19 companies in 2025. Trend: 2023 $1,451 · 2024 $1,697 · 2025 $2,400
Food & beverage: $2,400
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 41 | $385 |
| AstraZeneca Pharmaceuticals LP | 19 | $344 |
| Otsuka America Pharmaceutical, Inc. | 14 | $252 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $201 |
| Lilly USA, LLC | 13 | $174 |
| PFIZER INC. | 12 | $150 |
| Sumitomo Pharma America, Inc. | 9 | $139 |
| Viatris Specialty LLC | 11 | $139 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $136 |
| Novo Nordisk Inc | 6 | $99 |
Products named: REXULTI, UBRELVY, CAPLYTA, AIRSUPRA, GEMTESA, YUPELRI, ELIQUIS, XIFAXAN.
Industry payments across AR — which companies pay providers there.
